WuXi Biologics
Offering End-to-End Solutions
Conventional lysine- or cysteine-based conjugation results in heterogeneous ADC products due to a wide drug-to-antibody ratio(DAR) distribution. Over the last decade, many site-specific conjugation technologies have been developed to address this issue, yet the improved homogeneity usually comes at a cost. To address these issues, WuXi XDC developed WuXiDAR2™, WuXiDAR4™ and WuXiDAR6™, collectively referred to as the WuXiDARx technology platform.
This scientific poster was originally presented during the 2023 World ADC Conference in San Diego
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?